ClinicalTrials.gg
CompletedNCT01962922Updated Jun 6, 2018Results posted

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

A Phase 3 interventional study of LCP-Tacro and Tacrolimus -IR in Renal Failure, sponsored by Veloxis Pharmaceuticals. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by Veloxis Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing tacrolimus in Renal Insufficiency — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Renal Insufficiency.

Enrollment
9th of 17
50 · median 50
Started
2013
the only one that year
Phase 3
6 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
8 of 17
Veloxis Pharmaceuticals

Among the 17 studies testing tacrolimus in Renal Insufficiency, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 3, and was the 13th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 17 studies testing tacrolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing tacrolimus in Renal Insufficiency as a file.
02

Study summary

Open label, prospective, single-center, randomized, two sequence, three period crossover study to compare the steady state pharmacokinetics of LCP-Tacro tables to generic tacrolimus capsules administered twice daily in stable African-American renal transplant patients.

Read the detailed description

This is open label, prospective, single-center, randomized, two sequence, three period crossover study to compare the steady state pharmacokinetics of once daily dosing of LCP-Tacro tablets to tacrolimus capsules administered twice daily in stable African American kidney transplant patients.

Approximately 72 male and female African American renal transplant patients on table immunosuppression regimens will be randomly assigned in a 1:1 ratio to one of two sequences:

Sequence 1: (n=36) 18 patients requiring less than 0.15 mg/kg/day and 18 patients requiring equal to or greater than 0.15 mg/kg/day. Patients will continue on generic tacrolimus capsules on days 1-7 (24 hours PK profile on day 7) then patients are switched to LCP-Tacro tablets (at 15% lower dose of twice daily generic tacrolimus) on day 8.

Sequence 2: (n=36) 18 patients requiring less than 0.15 mg/kg/day and 18 patients requiring equal to or greater than 0.15 mg/kg/day. Patients will receive LCP-Tacro tablets (at 15% lower dose than generic tacrolimus twice daily formulation) on days 1-7 (24 hour PK profile on day 7) patients are switched back to twice daily generic tacrolimus treatment beginning on day 8.

03

Conditions studied

  • Renal Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18-80 old, male or female
  • African Americans
  • Willing to give written and to comply with study visits and restrictions, including being able to speak, write and understand English
  • Pt who have received a primary or secondary transplant
  • Pt least 6 (six) mth post-transplant and on a stable dose of tacrolimus
  • ≥19
  • Pt who are sero-positive for or C positive may also be enrolled
  • Pt maintained on concurrent with stable doses during screening
  • Pt on a proton PPI remain on the same PPI formulation and dose during the PK portion of the study.
  • During PK phase Only: Pt taking any medication that could interfere with tacrolimus blood levels, including prescription and over-the-counter medications, herbal or food supplements (including grapefruit, and pomegranate products), or medications must continue the same dose and are willing to continue the same dose/routine
  • During PK phase Only: the patient is not scheduled to begin any new medication that could interfere with tacrolimus blood levels, including prescription and over-the-counter medications, herbal or food

Exclusion criteria

Exclusion Criteria:

  • Evidence of acute rejection episode within the past three months
  • Pt not Africa-American
  • Recipients of organ transplants other than kidney
  • Known to be positive at transplant
  • Pt with recurrent focal segmental glomerulosclerosis (FSGS)
  • Pt with any severe medical condition (including infection) requiring acute or chronic treatment
  • Pt with a positive DSA
  • Pt with a positive BK virus results
  • \< 25 ml/min measured by MDRD4 as SOC within last 30 days
  • Patients with , ALT, total > 2.5 x or evidence of severe liver disease
  • Pt with WBC \< to 2000/mm3 or ANC \< to 1500 mm3 with \< 75,000/mm3 or HGB \< 8 g/dl
  • Pt with mental or physical conditions or known non-adherence
  • Presence of intractable complications of side effects resulting in dose adjustment of tacrolimus
  • Exposed to therapy within 30 days prior to enrollment
  • No anticipated changes in the immunosuppressive regimen, other than those specified by the study protocol
  • Pt with severe diabetic gastroparesis or other severe GI disturbances
  • Pt who have underwent gastric banding or gastric bypass at any time pre or post-transplant
  • Pregnant or nursing (lactating) women, or planning to become pregnant
  • Women of , defined as all women physiologically capable of becoming pregnant who are unwilling to use a defined SOC of method
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    LCP-Tacro

    Envarsus XR

    Drug: LCP-Tacro

  • Active comparator
    Tacrolimus - IR

    Tacrolimus

    Drug: Tacrolimus -IR

Interventions

  • once-daily extended release tablet

    Also known as: Envarsus XR

  • twice daily capsules

    Also known as: Prograf, Generic Tacrolimus

06

What researchers measure

Primary outcomes

  1. Evaluation of AUC(0-24) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

    Time frame: Day 7

  2. Evaluation of C(Max) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

    Time frame: Day 7

  3. Evaluation of C(Min) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

    Time frame: Day 7

  4. Evaluation of AUC(0-24) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

    Time frame: Day 14

  5. Evaluation of C(Max) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

    Time frame: Day 14

  6. Evaluation of C(Min) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours

    Time frame: Day 14

  7. Evaluation of AUC(0-24) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

    Time frame: Day 21

  8. Evaluation of C(Max) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

    Time frame: Day 21

  9. Evaluation of C(Min) for Envarsus XR and IR-Tac

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

    Time frame: Day 21

07

Results

Posted Aug 15, 2016

Participant flow

25 November 2013 (first patient enrolled) to 09-Mar-2015 (last patient completed initial pharmacokinetics \[PK\] portion of the study, the 'PK Cross-over' period), approximately 16 months enrolled from 3 US medical centers:University of Pennsylvania;University of Illinois at Chicago;Washington School of Medicine

PK Portion Day 7
Participant flow — PK Portion Day 7
MilestoneSequence 1Sequence 2
Started2723
Completed2323
Not completed40
Withdrew: Withdrawal by subject30
Withdrew: Non-compliance10
PK Portion Day 14
Participant flow — PK Portion Day 14
MilestoneSequence 1Sequence 2
Started2323
Completed2323
Not completed00
PK Portion Day 21
Participant flow — PK Portion Day 21
MilestoneSequence 1Sequence 2
Started2323
Completed2323
Not completed00
Extendion Portion (up to Month 6)
Participant flow — Extendion Portion (up to Month 6)
MilestoneSequence 1Sequence 2
Started2323
Completed1820
Not completed53
Withdrew: No longer wished to participate in study43
Withdrew: Physician decision10

Outcome measures

PrimaryEvaluation of AUC(0-24) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

Time frame:
Day 7
Reported as:
Mean · ng*hr/mL
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac
ng*hr/mLEnvarsus XRTacrolimus - IR
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac251.9 ± 77.78247.9 ± 102.33
PrimaryEvaluation of C(Max) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

Time frame:
Day 7
Reported as:
Mean · ng/mL
Evaluation of C(Max) for Envarsus XR and IR-Tac
ng/mLEnvarsus XRTacrolimus - IR
Evaluation of C(Max) for Envarsus XR and IR-Tac16.53 ± 5.46426.84 ± 13.296
PrimaryEvaluation of C(Min) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

Time frame:
Day 7
Reported as:
Mean · ng/mL
Evaluation of C(Min) for Envarsus XR and IR-Tac
ng/mLEnvarsus XRTacrolimus - IR
Evaluation of C(Min) for Envarsus XR and IR-Tac7.51 ± 2.4877.06 ± 2.843
PrimaryEvaluation of AUC(0-24) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

Time frame:
Day 14
Reported as:
Mean · ng*hr/mL
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac
ng*hr/mLEnvarsus XRTacrolimus - IR
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac293.3 ± 124.40225.7 ± 56.27
PrimaryEvaluation of C(Max) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

Time frame:
Day 14
Reported as:
Mean · ng/mL
Evaluation of C(Max) for Envarsus XR and IR-Tac
ng/mLEnvarsus XRTacrolimus - IR
Evaluation of C(Max) for Envarsus XR and IR-Tac20.83 ± 9.26526.31 ± 13.296
PrimaryEvaluation of C(Min) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours

Time frame:
Day 14
Reported as:
Mean · ng/mL
Evaluation of C(Min) for Envarsus XR and IR-Tac
ng/mLEnvarsus XRTacrolimus - IR
Evaluation of C(Min) for Envarsus XR and IR-Tac8.34 ± 3.7696.46 ± 1.692
PrimaryEvaluation of AUC(0-24) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

Time frame:
Day 21
Reported as:
Mean · ng*hr/mL
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac
ng*hr/mLEnvarsus XRTacrolimus - IR
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac289.3 ± 111.79230.3 ± 53.83
PrimaryEvaluation of C(Max) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

Time frame:
Day 21
Reported as:
Mean · ng/mL
Evaluation of C(Max) for Envarsus XR and IR-Tac
ng/mLEnvarsus XRTacrolimus - IR
Evaluation of C(Max) for Envarsus XR and IR-Tac19.71 ± 8.38726.31 ± 7.871
PrimaryEvaluation of C(Min) for Envarsus XR and IR-Tac

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.

Time frame:
Day 21
Reported as:
Mean · ng/mL
Evaluation of C(Min) for Envarsus XR and IR-Tac
ng/mLEnvarsus XRTacrolimus - IR
Evaluation of C(Min) for Envarsus XR and IR-Tac8.01 ± 3.2816.62 ± 1.692

Adverse events

Collected over Adverse events were collected from start of first dose of study medication, through and including last dose of study medication during the up to 6 month extension period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Envarsus XR—3/50 (6%)23/50 (46%)
Tacrolimus - IR—4/50 (8%)22/50 (44%)
Most frequent serious events
Most frequent serious events
EventEnvarsus XRTacrolimus - IR
CellulitisInfections and infestations1/500/50
Corona virus infectionInfections and infestations0/501/50
Gastroenteritis viralInfections and infestations0/501/50
Otitis MediaInfections and infestations1/500/50
PneumoniaInfections and infestations1/500/50
Acute renal failureRenal and urinary disorders1/501/50
HypoxiaRespiratory, thoracic and mediastinal disorders1/500/50
Deep vein thrombosisVascular disorders0/501/50
Cardiac failure acuteCardiac disorders0/501/50
HyperglycemiaMetabolism and nutrition disorders0/501/50
Most frequent other events
Most frequent other events
EventEnvarsus XRTacrolimus - IR
Blood creatinine increasedInvestigations7/504/50
NasopharyngitisInfections and infestations3/505/50
Glomerular filtration rate decreasedInvestigations5/501/50
HeadacheNervous system disorders2/505/50
ConstipationGastrointestinal disorders0/503/50
DiarrhoeaGastrointestinal disorders3/503/50
NauseaGastrointestinal disorders3/503/50
HypomagnesaemiaMetabolism and nutrition disorders0/503/50
Pain in extremityMusculoskeletal and connective tissue disorders0/503/50

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sequence ISequence IITotal
<=18 years000
Between 18 and 65 years262046
>=65 years134
Sex: Female, Male
Sex: Female, Male(Participants)Sequence ISequence IITotal
Female12921
Male151429
Region of Enrollment
Region of Enrollment(participants)Sequence ISequence IITotal
United States272350
08

Study locations

3 sites
  • University of Illinois, Chicago
    Chicago, Illinois 60612, United States
  • Washingto University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, Nigro V, Bloom RD. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. Am J Kidney Dis. 2018 Mar;71(3):315-326. doi: 10.1053/j.ajkd.2017.07.018. Epub 2017 Nov 20. PubMed 29162334 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jul 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2013
First posted
Oct 14, 2013
Start
Nov 2013
Primary completionActual
Jul 2015
CompletionActual
Aug 2015
Results first posted
Aug 15, 2016
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01962922
Lead sponsor
Veloxis Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 14, 2013
Start date
Nov 2013
Primary completion
Jul 2015
Completion
Aug 2015
Results posted
Aug 15, 2016
Last update
Jun 6, 2018

Study contacts

Leslie Callahan, RN
study director · Veloxis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion